RT Journal Article
T1 Bengamide Analogues Show A Potent Antitumor Activity against Colon Cancer Cells: A Preliminary Study.
A1 Garcia-Pinel, Beatriz
A1 Porras-Alcala, Cristina
A1 Cabeza, Laura
A1 Ortiz, Raul
A1 Prados, Jose
A1 Melguizo, Consolacion
A1 Cheng-Sanchez, Ivan
A1 Lopez-Romero, Juan Manuel
A1 Sarabia, Francisco
K1 analogues
K1 antitumor agents
K1 bengamides
K1 colorectal cancer
K1 synthesis
AB The limited success and side effects of the current chemotherapeutic strategies against colorectal cancer (CRC), the third most common cancer worldwide, demand an assay with new drugs. The prominent antitumor activities displayed by the bengamides (Ben), a family of natural products isolated from marine sponges of the Jaspidae family, were explored and investigated as a new option to improve CRC treatment. To this end, two potent bengamide analogues, Ben I (5) and Ben V (10), were selected for this study, for which they were synthesized according to a new synthetic strategy recently developed in our laboratories. Their antitumor effects were analyzed in human and mouse colon cell lines, using cell cycle analysis and antiproliferative assays. In addition, the toxicity of the selected analogues was tested in human blood cells. These biological studies revealed that Ben I and V produced a significant decrease in CRC cell proliferation and induced a significant cell cycle alteration with a greater antiproliferative effect on tumor cell lines than normal cells. Interestingly, no toxicity effects were detected in blood cells for both compounds. All these biological results render the bengamide analogues Ben I and Ben V as promising antitumoral agents for the treatment of CRC.
PB MDPI AG
YR 2020
FD 2020-05-02
LK http://hdl.handle.net/10668/15505
UL http://hdl.handle.net/10668/15505
LA en
NO García-Pinel B, Porras-Alcalá C, Cabeza L, Ortiz R, Prados J, Melguizo C, et al. Bengamide Analogues Show A Potent Antitumor Activity against Colon Cancer Cells: A Preliminary Study. Mar Drugs. 2020 May 2;18(5):240.
DS RISalud
RD Apr 18, 2025